Whalley, Diane
Svedsater, Henrik
Doward, Lynda
Crawford, Rebecca
Leather, David
Lay-Flurrie, James
Bosanquet, Nick
Funding for this research was provided by:
GlaxoSmithKline (H0-19-1241/117375, H0-19-1241/117375, H0-19-1241/117375, H0-19-1241/117375, H0-19-1241/117375, H0-19-1241/117375, H0-19-1241/117375)
Article History
Received: 25 April 2018
Accepted: 5 March 2019
First Online: 9 May 2019
Competing interests
: D.W., L.D. and R.C. are employees of RTI Health Solutions, which has received funding from GlaxoSmithKline plc. H.S., D.L. and J.L.F. are GlaxoSmithKline plc. employees and hold GlaxoSmithKline plc. shares. N.B. was a chief investigator for the SLS COPD follow-up interviews and received a fee from GlaxoSmithKline plc.